A feasibility study of different commercially available serum-free mediums to enhance lentivirus and adeno-associated virus production in HEK 293 suspension cells.

AAV2 LV Suspension cell culture Transfection media Virus production

Journal

Cytotechnology
ISSN: 0920-9069
Titre abrégé: Cytotechnology
Pays: United States
ID NLM: 8807027

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 29 07 2022
accepted: 30 09 2022
entrez: 17 11 2022
pubmed: 18 11 2022
medline: 18 11 2022
Statut: ppublish

Résumé

Lentivirus and adeno-associated viruses are invaluable tools for biotechnology applications due to their genetic material delivery abilities both in vitro and in vivo. However, their large-scale productions with Good Manufacturing Practices yield low efficiency when adherent and serum dependent HEK293 (Human Embryonic Kidney) cells are used as the host. To increase production efficiency, HEK293 cells are adapted to grow in suspension using commercially available and chemically defined serum-free mediums. Suspended cells can be transiently transfected for viral vector production; however, significant improvements are still needed to increase yield and thereby cost effectiveness. Here, we evaluated four most preferred commercially available mediums that are IVY, FreeStyle293, LV-MAX, and BalanCD HEK293 for the transient transfection feasibility of lentiviral (LV) and adeno-associated virus serotype 2 (AAV2) production in FlorabioHEK293 suspension cells. The highest transfection efficiency was over 90% and obtained by using polyethyleneimine (PEI) 25 K and by media adaptation in IVY without using any transfection enhancer. For the first time the feasibility of HEK293 cells, which were adapted to grow in suspension culture by Florabio and IVY media, were tested for virus production. This study demonstrates the best transfection medium for scalable and optimized production of Lentivirus and Adeno-Associated Virus in suspended HEK293 cell culture. The online version contains supplementary material available at 10.1007/s10616-022-00551-1.

Identifiants

pubmed: 36389283
doi: 10.1007/s10616-022-00551-1
pii: 551
pmc: PMC9652196
doi:

Types de publication

Journal Article

Langues

eng

Pagination

635-655

Informations de copyright

© The Author(s), under exclusive licence to Springer Nature B.V. 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Oncol Lett. 2015 Jan;9(1):55-62
pubmed: 25435933
Mol Biotechnol. 2006 Oct;34(2):191-9
pubmed: 17172664
Thorax. 2017 Feb;72(2):137-147
pubmed: 27852956
Mol Ther Methods Clin Dev. 2020 Jun 03;18:312-320
pubmed: 32671134
J Virol. 2000 Nov;74(21):10074-80
pubmed: 11024136
Appl Microbiol Biotechnol. 2015 Dec;99(23):9935-49
pubmed: 26278533
Future Oncol. 2022 Jan;18(2):245-259
pubmed: 34821517
Gene Ther. 2019 Nov;27(10-11):482-494
pubmed: 32341483
Mol Ther. 2016 Feb;24(2):287-297
pubmed: 26437810
Biotechnol Prog. 2003 May-Jun;19(3):833-43
pubmed: 12790647
Methods Mol Biol. 2012;801:13-26
pubmed: 21987244
Prog Retin Eye Res. 2021 Jul;83:100915
pubmed: 33069860
Iran J Pharm Res. 2019 Fall;18(Suppl1):146-156
pubmed: 32802095
Mol Ther Methods Clin Dev. 2020 Mar 30;17:717-730
pubmed: 32346549
Gene Ther. 2018 Jan;25(1):39-46
pubmed: 29345252
Hum Gene Ther Methods. 2012 Feb;23(1):18-28
pubmed: 22428977
Eur J Pharm Biopharm. 2011 Jun;78(2):184-8
pubmed: 21256214
Signal Transduct Target Ther. 2021 Feb 8;6(1):53
pubmed: 33558455
Mol Ther Methods Clin Dev. 2017 Mar 08;5:22-30
pubmed: 28480301
Hum Gene Ther. 1995 Sep;6(9):1195-202
pubmed: 8527478
Cold Spring Harb Protoc. 2019 Oct 1;2019(10):
pubmed: 31575795
Biotechnol J. 2021 Jan;16(1):e2000017
pubmed: 32686901
Hum Gene Ther. 2009 Jul;20(7):698-706
pubmed: 19438300
Cytotechnology. 1994;15(1-3):3-9
pubmed: 7765943
Cytotechnology. 2014 May;66(3):493-514
pubmed: 23775287
Sci Rep. 2018 Mar 27;8(1):5271
pubmed: 29588490
Mol Ther Methods Clin Dev. 2018 Nov 22;13:14-26
pubmed: 30591923
J Virol Methods. 2013 Sep;192(1-2):28-38
pubmed: 23624118
Biomater Res. 2019 Mar 12;23:8
pubmed: 30915230
J Virol Methods. 2006 Dec;138(1-2):85-98
pubmed: 16950522
Methods Mol Biol. 2017;1603:45-55
pubmed: 28493122
Hum Gene Ther. 2011 Mar;22(3):343-56
pubmed: 21043787
Gene Ther. 2001 Sep;8(17):1281-90
pubmed: 11571564
J Virol Methods. 2014 Feb;196:163-73
pubmed: 24239634
Hum Mol Genet. 1996 May;5(5):591-4
pubmed: 8733124
Cytotechnology. 2015 Aug;67(4):689-97
pubmed: 25149286
Hum Gene Ther. 2003 Sep 20;14(14):1287-96
pubmed: 14503964
Viruses. 2020 Jan 09;12(1):
pubmed: 31936491
Front Chem Eng. 2022;4:
pubmed: 35685827
Hum Gene Ther. 2019 Dec;30(12):1559-1571
pubmed: 31637925
Methods. 2011 Sep;55(1):44-51
pubmed: 21539918
Sci Rep. 2017 Mar 08;7:44134
pubmed: 28272487
Cytotechnology. 2013 Mar;65(2):263-71
pubmed: 22782435
Viruses. 2021 Feb 09;13(2):
pubmed: 33572347
Cell Host Microbe. 2021 Feb 10;29(2):236-249.e6
pubmed: 33357418
J Gen Virol. 1977 Jul;36(1):59-74
pubmed: 886304
Methods Enzymol. 2013;529:227-40
pubmed: 24011049
Nat Biotechnol. 2005 Mar;23(3):321-8
pubmed: 15735640
Bioprocess Int. 2012 Feb;10(2):32-43
pubmed: 22707919
J Transl Med. 2021 Nov 24;19(1):474
pubmed: 34819105
Biomed Opt Express. 2016 Apr 04;7(5):1672-89
pubmed: 27231613
J Vis Exp. 2015 Dec 28;(106):e53568
pubmed: 26779721
Mol Ther Methods Clin Dev. 2021 Apr 16;21:642-655
pubmed: 34095346
Curr Protoc Microbiol. 2012 Aug;Chapter 14:Unit14D.1
pubmed: 22875565
J Membr Biol. 2014 Dec;247(12):1259-67
pubmed: 25146882
BioDrugs. 2017 Aug;31(4):317-334
pubmed: 28669112
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
ALTEX. 2010;27(1):53-62
pubmed: 20390239
Metab Brain Dis. 2021 Jan;36(1):45-52
pubmed: 33201426
Sci Rep. 2015 Mar 12;5:9021
pubmed: 25762005
Hum Vaccin. 2008 Sep-Oct;4(5):350-9
pubmed: 18382143

Auteurs

Gizem Celebi Torabfam (G)

Sabanci University Nanotechnology Research and Application Center (SUNUM), Istanbul, 34956 Turkey.
Faculty of Engineering and Natural Sciences, Molecular Biology, Genetics, and Bioengineering Program, Sabanci University, Istanbul, 34956 Turkey.

Abuzer Alp Yetisgin (AA)

Sabanci University Nanotechnology Research and Application Center (SUNUM), Istanbul, 34956 Turkey.
Faculty of Engineering and Natural Sciences, Materials Science and Nano Engineering, Sabanci University, Istanbul, 34956 Turkey.

Cem Erdem (C)

FloraBio Technology, Urla, 35430 İzmir Turkey.

Aziz Cayli (A)

FloraBio Technology, Urla, 35430 İzmir Turkey.

Ozlem Kutlu (O)

Sabanci University Nanotechnology Research and Application Center (SUNUM), Istanbul, 34956 Turkey.
Faculty of Engineering and Natural Sciences, Molecular Biology, Genetics, and Bioengineering Program, Sabanci University, Istanbul, 34956 Turkey.

Sibel Cetinel (S)

Sabanci University Nanotechnology Research and Application Center (SUNUM), Istanbul, 34956 Turkey.
Faculty of Engineering and Natural Sciences, Molecular Biology, Genetics, and Bioengineering Program, Sabanci University, Istanbul, 34956 Turkey.

Classifications MeSH